Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00669903 · ClinicalTrials.gov registry record · Phase 2
Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00669903 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 100 participants.
The verdict
NCT00669903, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study is to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of multiple ascending doses of AZD0328 in patients with schizophrenia
Interventions
- DRUG Placebo
- DRUG AZD0328
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00669903
The ClinicalTrials.gov registry entry for NCT00669903 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00669903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00669903 about?
NCT00669903 is a clinical study titled "Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia". This study is to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of multiple ascending doses of AZD0328 in patients with schizophrenia
What is the current status of trial NCT00669903?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2008-04. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00669903?
The interventions under investigation include: Placebo (DRUG), AZD0328 (DRUG).
Who is sponsoring clinical trial NCT00669903?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.